Business
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September 10, 2025. The Company believes Mr. Kane and Ms. Hemrajani add valuable expertise in finance, business development, product commercialization, and corporate strategy to its Board of Directors as the Company adva
About this update from Lb Pharmaceuticals Inc
[{"type":"image","alt":"LB Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"LB Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":208,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/7ec9cdef8e7ca23d2ed6879c46ed3d01"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mAfHG8UMaaqGe4Sknv3Sdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7ec9cdef8e7ca23d2ed6879c46ed3d01","width":208,"height":200}},"lazy":false},{"type":"text","content":"NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September 10, 2025. The Company believes Mr. Kane and Ms. Hemrajani add valuable expertise in finance, business development, product commercialization, and corporate strategy to its Board of Directors as the Company advances its lead product candidate, LB-102, into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression. LB Pharmaceuticals is building a pipeline that leverages the broad therapeutic potential of LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.","length":899,"tagName":"p"},{"type":"text","content":"“Ms. Hemrajani and Mr. Kane have complementary strengths that will accelerate our strategic growth as we approach the initiation of two important clinical trials early next year,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals. “Ms. Hemrajani’s experience in financial operations and corporate governance and Mr. Kane’s proven track record of commercializing new therapies make them outstanding additions to our Board of Directors. Their guidance will be invaluable as we work to fulfill our mission of bringing safer, more effective neuropsychiatric treatments to patients.”","length":595,"tagName":"p"},{"type":"text","content":"Mr. Kane brings over three decades of biopharmaceutical leadership to the Board. He is currently President and CEO of Uniquity Bio. He was previously President and CCO at Anthos Therapeutics (through its acquisition by Novarti...